查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594696

口服固体製剂契约製造市场：按产品、机制和最终用户划分 - 全球预测 2025-2030

Oral Solid Dosage Contract Manufacturing Market by Product (Capsules, Granules, Gummies), Mechanism (Controlled-Release, Delayed-Release, Immediate-Release), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年口服固体製剂契约製造市值为408.3亿美元，预计到2024年将达到441.6亿美元，复合年增长率为8.63%，到2030年将达到729.1亿美元。

口服固体製剂（OSD）契约製造是指将锭剂、胶囊等固态剂型的製造委託给专门的第三方机构。这种方法可以帮助製药公司优化生产成本、利用先进技术并快速扩大营运规模。这项需求源自于缩短药物上市时间、应对复杂配方挑战以及遵守严格监管要求的压力。 OSD契约製造在各种应用中发挥重要作用，包括学名药製造、高效价药物和新型药物传输系统，最终用途涵盖品牌製药和生物技术公司。关键的成长要素包括对学名药的需求不断增加、连续生产等製造流程的技术进步以及慢性病盛行率的增加推动药品消费。

主要市场统计
基准年[2023] 408.3亿美元
预测年份 [2024] 441.6亿美元
预测年份 [2030] 729.1亿美元
复合年增长率（%） 8.63%

人工智慧和物联网等数位技术的融合正在创造新的商机，提高效率和可追溯性。公司可以透过投资智慧製造方法来利用这一点。然而，监管障碍、品管问题和供应链中断等限制带来了重大挑战。需要创新的领域是开发更永续的製造流程、解决环境问题并符合全球永续性趋势。另一个有前景的途径是个人化医疗，契约製造可以提供针对利基市场的解决方案。

随着市场竞争的加剧以及多家公司不断投资于研发以推出新颖的解决方案，策略伙伴关係关係至关重要。驾驭这一复杂的环境需要对技术整合、监管变化和客户需求有敏锐的了解。企业也应专注于加强供应链弹性并拥抱数位转型，以保持竞争优势。透过利用这些策略，公司不仅可以确保合规性和效率，而且还可以处于 OSD契约製造市场创新的前沿。

市场动态：快速发展的口服固体製剂契约製造市场的关键市场洞察

口服固体製剂的契约製造市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 製药公司越来越多地采用外包服务
    • 专利到期和学名药生产增加
    • 需要具有成本效益的药物开发过程
  • 市场限制因素
    • 缺乏经验丰富的技术人员
  • 市场机会
    • 药物开发技术的进步
    • CDMO 增加投资以扩大口服固态剂型 (OSD) 开发
  • 市场挑战
    • 严格的监管核准标准

波特五力：开拓口服固体製剂契约製造市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解口服固体製剂契约製造市场的外部影响

外部宏观环境因素在塑造口服固体製剂契约製造市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解口服固体製剂契约製造市场的竞争状况

口服固体製剂契约製造市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位基质口服固体製剂契约製造市场供应商的绩效评估

FPNV定位矩阵是评估口服固体製剂契约製造市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製口服固体製剂契约製造市场的成功之路

对于希望加强在全球市场的影响力的公司来说，口服固体製剂契约製造市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 药厂加大外包服务引进力度
      • 专利到期和学名药生产增加
      • 需要具有成本效益的药物开发过程
    • 抑制因素
      • 缺乏经验丰富的技术人员
    • 机会
      • 药物开发技术不断进步
      • CDMO 增加投资以扩大口服固体製剂(OSD) 开发
    • 任务
      • 严格的监管核准标准
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章口服固体製剂契约製造市场：副产品

  • 胶囊
  • 颗粒
  • 软糖
  • 菱形
  • 菱形
  • 粉末
  • 药片

第七章口服固体製剂契约製造市场：依组织划分

  • 控释
  • 延迟释放
  • 即时释放

第八章口服固体製剂契约製造市场：依最终用户分类

  • 大公司
  • 中型企业/中小企业
  • Start-Ups和学名药公司

第九章北美及南美口服固体製剂契约製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太口服固体製剂契约製造市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲口服固体製剂的契约製造市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Aenova Holding GmbH
  • Alcami Corporation, Inc.
  • Aphena Pharma Solutions
  • Ardena Holding NV
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Corden Pharma International GmbH
  • GlaxoSmithKline PLC
  • Hermes Pharma GmbH
  • Jubilant Pharma Holdings Inc.
  • Lonza Group Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Piramal Group
  • Recipharm AB
Product Code: MRR-0D217D5AE60A

The Oral Solid Dosage Contract Manufacturing Market was valued at USD 40.83 billion in 2023, expected to reach USD 44.16 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 72.91 billion by 2030.

Oral Solid Dosage (OSD) Contract Manufacturing refers to the outsourcing of the production of solid pharmaceutical forms, such as tablets and capsules, to specialized third-party organizations. This approach supports pharmaceutical companies in optimizing production costs, accessing advanced technologies, and scaling operations rapidly. The necessity arises from the increasing pressure to reduce time-to-market for drugs, manage complex formulation challenges, and comply with stringent regulatory requirements. OSD contract manufacturing is critical in various applications, including generic drug production, high-potency drugs, and novel drug delivery systems, with end-use spanning both branded pharmaceuticals and biotechnology firms. Key growth factors include escalating demand for generics, technological advancements in manufacturing processes such as continuous production, and the increasing prevalence of chronic diseases which boost drug consumption.

KEY MARKET STATISTICS
Base Year [2023] USD 40.83 billion
Estimated Year [2024] USD 44.16 billion
Forecast Year [2030] USD 72.91 billion
CAGR (%) 8.63%

Emerging opportunities are being driven by the integration of digital technologies like AI and IoT, improving efficiency and traceability. Companies can capitalize on this by investing in smart manufacturing practices. However, limitations such as regulatory hurdles, quality control issues, and supply chain disruptions pose significant challenges. An area for innovation is the development of more sustainable manufacturing processes, addressing environmental concerns and aligning with global sustainability trends. Another promising avenue is personalized medicine, where contract manufacturers can provide tailored solutions for niche markets.

The market exhibits significant competitive intensity with several players continually investing in R&D to introduce novel solutions, making strategic partnerships vital. Successful navigation of this intricate landscape requires a keen understanding of technology integration, regulatory changes, and customer demands. Businesses should also focus on enhancing supply chain resilience and embracing digital transformation to maintain competitive advantage. By leveraging these strategies, companies not only ensure compliance and efficiency but also position themselves at the forefront of innovation in the OSD contract manufacturing market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oral Solid Dosage Contract Manufacturing Market

The Oral Solid Dosage Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of outsourcing services by pharmaceutical companies
    • Increasing patent expiration and generic drug manufacturing
    • Need for cost-effective drug development process
  • Market Restraints
    • Less availability of experienced technical staff
  • Market Opportunities
    • Increase in the advancement of drug development technology
    • Rising investments by CDMOs to expand the oral solid dosage (OSD) development
  • Market Challenges
    • Strict approval criteria by regulatory authorities

Porter's Five Forces: A Strategic Tool for Navigating the Oral Solid Dosage Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oral Solid Dosage Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oral Solid Dosage Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oral Solid Dosage Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oral Solid Dosage Contract Manufacturing Market

A detailed market share analysis in the Oral Solid Dosage Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oral Solid Dosage Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oral Solid Dosage Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oral Solid Dosage Contract Manufacturing Market

A strategic analysis of the Oral Solid Dosage Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oral Solid Dosage Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Aenova Holding GmbH, Alcami Corporation, Inc., Aphena Pharma Solutions, Ardena Holding NV, Boehringer Ingelheim International GmbH, Cambrex Corporation, Corden Pharma International GmbH, GlaxoSmithKline PLC, Hermes Pharma GmbH, Jubilant Pharma Holdings Inc., Lonza Group Ltd., Novartis AG, Pfizer Inc., Piramal Group, and Recipharm AB.

Market Segmentation & Coverage

This research report categorizes the Oral Solid Dosage Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Capsules, Granules, Gummies, Lozenges, Pastilles, Powders, and Tablets.
  • Based on Mechanism, market is studied across Controlled-Release, Delayed-Release, and Immediate-Release.
  • Based on End-User, market is studied across Large-Size Companies, Medium- & Small-Size Companies, and Startups & Generic Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of outsourcing services by pharmaceutical companies
      • 5.1.1.2. Increasing patent expiration and generic drug manufacturing
      • 5.1.1.3. Need for cost-effective drug development process
    • 5.1.2. Restraints
      • 5.1.2.1. Less availability of experienced technical staff
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in the advancement of drug development technology
      • 5.1.3.2. Rising investments by CDMOs to expand the oral solid dosage (OSD) development
    • 5.1.4. Challenges
      • 5.1.4.1. Strict approval criteria by regulatory authorities
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oral Solid Dosage Contract Manufacturing Market, by Product

  • 6.1. Introduction
  • 6.2. Capsules
  • 6.3. Granules
  • 6.4. Gummies
  • 6.5. Lozenges
  • 6.6. Pastilles
  • 6.7. Powders
  • 6.8. Tablets

7. Oral Solid Dosage Contract Manufacturing Market, by Mechanism

  • 7.1. Introduction
  • 7.2. Controlled-Release
  • 7.3. Delayed-Release
  • 7.4. Immediate-Release

8. Oral Solid Dosage Contract Manufacturing Market, by End-User

  • 8.1. Introduction
  • 8.2. Large-Size Companies
  • 8.3. Medium- & Small-Size Companies
  • 8.4. Startups & Generic Pharmaceutical Companies

9. Americas Oral Solid Dosage Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oral Solid Dosage Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aenova Holding GmbH
  • 2. Alcami Corporation, Inc.
  • 3. Aphena Pharma Solutions
  • 4. Ardena Holding NV
  • 5. Boehringer Ingelheim International GmbH
  • 6. Cambrex Corporation
  • 7. Corden Pharma International GmbH
  • 8. GlaxoSmithKline PLC
  • 9. Hermes Pharma GmbH
  • 10. Jubilant Pharma Holdings Inc.
  • 11. Lonza Group Ltd.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Piramal Group
  • 15. Recipharm AB

LIST OF FIGURES

  • FIGURE 1. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GUMMIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY LOZENGES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PASTILLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DELAYED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY LARGE-SIZE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MEDIUM- & SMALL-SIZE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STARTUPS & GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023